Physician profile
Michael Tapscott
NPI 1053803718
$1,215.36
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.58 · 2021: $268 · 2022: $662 · 2023: $253 · 2024: $15.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $263.03 | 2021-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $199.33 | 2021-2023 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $145.79 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $131.41 | 2021-2023 | Breztri |
| Abbvie INC. | $87.99 | 2022-2023 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.22 | 2021-2022 | |
| Pfizer INC. | $46.03 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $45.09 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $40.56 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.77 | 2021-2022 | |
| Amgen INC. | $30.07 | 2021-2024 | Prolia, Evenity |
| Lilly USA, LLC | $23.69 | 2022 | |
| Abbott Laboratories | $20.29 | 2023 | Freestyle Libre 2 |
| Mylan Specialty L.P. | $18.99 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $16.58 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tapscott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.